| P2Y purinoceptor 1 |
EC50 |
= |
2800.0 |
nM |
Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of turkey erythrocytes |
CHEMBL1135773 |
| Purinergic receptor P2Y2 |
EC50 |
= |
230.0 |
nM |
Evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 2 (P2Y2) |
CHEMBL1135773 |
| Pyrimidinergic receptor P2Y4 |
EC50 |
= |
43000.0 |
nM |
The compound was evaluated for antagonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 4 (P2Y4) |
CHEMBL1135773 |
| Pyrimidinergic receptor P2Y4 |
EC50 |
= |
1800.0 |
nM |
The compound was evaluated for agonist activity against phospholipase C coupled recombinant rat P2Y purinoceptor 4 (P2Y4) |
CHEMBL1135773 |
| Pyrimidinergic receptor P2Y6 |
EC50 |
> |
100000.0 |
nM |
The compound was evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 6 (P2Y6) |
CHEMBL1135773 |
| Purinergic receptor P2Y11 |
EC50 |
= |
17000.0 |
nM |
Agonist activity against phospholipase C coupled human P2Y purinoceptor 11 (P2Y11) |
CHEMBL1135773 |
| Purinergic receptor P2Y12 |
EC50 |
= |
3190.0 |
nM |
Antagonist activity against phospholipase C coupled rat P2Y purinoceptor 12 (P2Y12) |
CHEMBL1135773 |
| P2X purinoceptor 1 |
EC50 |
= |
56.0 |
nM |
Antagonist activity against recombinant human P2X purinoceptor 1 (P2X1 ) |
CHEMBL1135773 |
| P2X purinoceptor 2 |
EC50 |
= |
1400.0 |
nM |
Antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 10 uM, expressed in Xenopus oocytes |
CHEMBL1135773 |
| P2X purinoceptor 3 |
EC50 |
= |
340.0 |
nM |
Antagonist activity against recombinant human P2X purinoceptor 3 (P2X3 ) |
CHEMBL1135773 |
| P2X purinoceptor 4 |
EC50 |
= |
500.0 |
nM |
Antagonist activity against recombinant human P2X purinoceptor 4 (P2X4) |
CHEMBL1135773 |
| P2X purinoceptor 4 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 30 uM, expressed in Xenopus oocytes |
CHEMBL1135773 |
| P2X purinoceptor 5 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity against recombinant rat P2X purinoceptor 5 (P2X5) |
CHEMBL1135773 |
| P2X purinoceptor 6 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity against recombinant rat P2X purinoceptor 6 (P2X6 ) |
CHEMBL1135773 |
| P2X purinoceptor 7 |
EC50 |
= |
780000.0 |
nM |
Antagonist activity against recombinant human P2X purinoceptor 7 (P2X7) |
CHEMBL1135773 |
| Unchecked |
K 0.5 |
= |
2800.0 |
nM |
Agonism at turkey erythrocyte P2Y receptor. |
CHEMBL1127060 |
| Cavia porcellus |
Relative activity |
= |
6.2 |
|
Tested for relaxation of carbachol-contracted guinea pig taenia coli at 37 degree C |
CHEMBL1127060 |
| Oryctolagus cuniculus |
Relative activity |
= |
4.5 |
|
Tested for relaxation of carbachol-contracted rabbit aorta at 37 degree C; Potency equal to 2MeSATP |
CHEMBL1127060 |
| Oryctolagus cuniculus |
Relative activity |
= |
6.0 |
|
Tested for relaxation of carbachol-contracted rabbit mesenteric artery at 37 degree C; Potency equal to 2MeSATP |
CHEMBL1127060 |
| Oryctolagus cuniculus |
Relative activity |
|
|
|
Tested for contraction of rabbit saphenous artery produced by 1 uM alpha,beta-MeATP at 37 degree C; Potency equal to ATP |
CHEMBL1127060 |
| Cavia porcellus |
Relative activity |
= |
3.5 |
|
Tested for contraction of guinea pig vas deferens at 37 degree C; Potency equal to ATP |
CHEMBL1127060 |
| Cavia porcellus |
Relative activity |
|
|
|
Tested for contraction of guinea pig isolated urinary bladder detrusor muscle at 37 degree C; Potency equal to ATP |
CHEMBL1127060 |
| Unchecked |
Radioactivity |
= |
8.4 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation), determined in the incubation medium of INS-1 cell membranes |
CHEMBL1144917 |
| Unchecked |
Radioactivity |
= |
4.0 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation), in presence of added Ap4A, in the incubation medium of INS-1 cell membranes |
CHEMBL1144917 |
| Unchecked |
Radioactivity |
= |
8.2 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation), in presence of added Ap(s)pCH2pp(s)A, in the incubation medium of INS-1 cell membranes |
CHEMBL1144917 |
| Rattus norvegicus |
Radioactivity |
= |
42.1 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation) in heparinized rat plasma (saline) |
CHEMBL1144917 |
| Rattus norvegicus |
Radioactivity |
= |
37.6 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation), in presence of added Ap(s)pCH2pp(s)A, in heparinized rat plasma |
CHEMBL1144917 |
| Rattus norvegicus |
Radioactivity |
= |
40.5 |
% |
Percent of compound radioactivity ([3H]-Ap4A Degradation), in presence of added Ap(s)pCHClpp(s)A, in heparinized rat plasma |
CHEMBL1144917 |
| Adenylate kinase 2 |
Km |
= |
90000.0 |
nM |
Concentration for half-maximal velocity for adenylate kinase (AK II) was determined |
CHEMBL1122067 |
| Adenylate kinase 2 |
Vmax |
= |
100.0 |
% |
Inhibitory constant of rat adenylate kinase (AK II) isozymes expressed as relative maximal velocity |
CHEMBL1122067 |
| Adenylate kinase 3 alpha like 1 |
Km |
= |
90000.0 |
nM |
Concentration for half-maximal velocity for adenylate kinase (AK III) was determined |
CHEMBL1122067 |
| Adenylate kinase 3 alpha like 1 |
Vmax |
= |
100.0 |
% |
Inhibitory constant of rat adenylate kinase (AK III) isozymes expressed as relative maximal velocity |
CHEMBL1122067 |
| Unchecked |
Km |
= |
570000.0 |
nM |
Concentration for half-maximal velocity for adenylate kinase (AK) was determined |
CHEMBL1122067 |
| Unchecked |
Vmax |
= |
100.0 |
% |
Inhibitory constant of rat adenylate kinase (AK) isozymes expressed as relative maximal velocity |
CHEMBL1122067 |
| P2Y purinoceptor 1 |
EC50 |
= |
6353.0 |
nM |
Agonistic activity for P2Y purinoceptor 1 of turkey erythrocyte membranes |
CHEMBL1132379 |
| Rattus norvegicus |
Km |
= |
90000.0 |
nM |
Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity |
CHEMBL1122037 |
| Rattus norvegicus |
Vmax |
= |
100.0 |
% |
Ability to inhibit rat adenylate kinase II, activity expressed as Maximum velocity |
CHEMBL1122037 |
| Rattus norvegicus |
Km |
= |
90000.0 |
nM |
Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity |
CHEMBL1122037 |
| Rattus norvegicus |
Vmax |
= |
100.0 |
% |
Ability to inhibit rat adenylate kinase III, activity expressed as Maximum velocity |
CHEMBL1122037 |
| Escherichia coli |
Km |
= |
60000.0 |
nM |
Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity |
CHEMBL1122037 |
| Escherichia coli |
Vmax |
= |
100.0 |
% |
Ability to inhibit Escherichia coli adenylate kinase II activity expressed as Maximum velocity |
CHEMBL1122037 |
| Rattus norvegicus |
Inhibition |
|
|
% |
Inhibition of Ca++ elevation was determined in CPX treated cardiac cells in rat; No inhibition |
CHEMBL1132304 |
| Rattus norvegicus |
Inhibition |
= |
60.0 |
% |
Inhibition of Ca++ elevation was determined in PPADS treated cardiac cells in rat |
CHEMBL1132304 |
| Ectonucleoside triphosphate diphosphohydrolase 1 |
Km |
= |
18000.0 |
nM |
Tested for inhibition of Nucleoside Triphosphate Diphosphohydrolase (NTPDase) from bovine spleen. |
CHEMBL1133102 |
| ADMET |
Velocity |
= |
100.0 |
% |
Tested for the velocity of 2.8 mM compound relative to that of 2.8 mM MgATP in the assay |
CHEMBL1122206 |
| Thymidine kinase, cytosolic |
Inhibition |
= |
0.0 |
% |
Compound was tested for the loss of thymidine kinase activity from Escherichia coli after 6 hr at 0 degrees C at 10 mM |
CHEMBL1122206 |
| Unchecked |
Relative velocity |
= |
1.0 |
|
Substrate activity against yeast hexokinase as 1:1 Mg complexes at 5.0 mM |
CHEMBL1122206 |
| Hexokinase type I |
Relative velocity |
= |
1.0 |
|
Substrate activity for rat hexokinase I as 1:1 Mg complex at 5.0 mM |
CHEMBL1122206 |
| Hexokinase type II |
Relative velocity |
= |
1.0 |
|
Substrate activity against Rat hexokinase II as 1:1 Mg complex at 5.0 mM |
CHEMBL1122206 |
| Hexokinase type III |
Relative velocity |
= |
1.0 |
|
Substrate activity for rat hexokinase III as 1:1 Mg complex at 5.0 mM |
CHEMBL1122206 |
| ADMET |
Km |
= |
130000.0 |
nM |
Substrate concentration for half maximal velocity was reported for yeast hexokinase |
CHEMBL1122206 |
| ADMET |
Vmax |
= |
100.0 |
% |
Compound was tested for substrate constants with yeast hexokinase. Maximal velocity Vmax was reported |
CHEMBL1122206 |
| ADMET |
Km |
= |
440000.0 |
nM |
Substrate concentration for half maximal velocity was reported for rat hexokinase I |
CHEMBL1122206 |
| ADMET |
Vmax |
= |
100.0 |
% |
Compound was tested for substrate constants with rat hexokinase. Maximal velocity Vmax was reported |
CHEMBL1122206 |
| ADMET |
Km |
= |
710000.0 |
nM |
Substrate concentration for half maximal velocity was reported for rat hexokinase II |
CHEMBL1122206 |
| ADMET |
Vmax |
= |
100.0 |
% |
Compound was tested for substrate constants with rat hexokinase. Maximal velocity Vmax was reported |
CHEMBL1122206 |
| ADMET |
Km |
= |
910000.0 |
nM |
Substrate concentration for half maximal velocity was reported for rat hexokinase III |
CHEMBL1122206 |
| ADMET |
Vmax |
= |
100.0 |
% |
Compound was tested for substrate constants with rat hexokinase. Maximal velocity Vmax was reported |
CHEMBL1122206 |
| Unchecked |
Inhibition |
= |
0.0 |
% |
Compound was tested for time dependent inhibition of hexokinase activity after 6 hr, at 0 degrees celsius, with 10 mM ATP derivative in yeast hexokinase |
CHEMBL1122206 |
| Hexokinase type I |
Inhibition |
= |
0.0 |
% |
Time dependent inhibition of Hexokinase type I activity after 6 h, at 0 degrees celsius, at 10 mM compound |
CHEMBL1122206 |
| Hexokinase type II |
Inhibition |
= |
0.0 |
% |
Time dependent inhibition of hexokinase 2 activity after 6 h, at 10 mM compound |
CHEMBL1122206 |
| Hexokinase type III |
Inhibition |
= |
0.0 |
% |
Time dependent inhibition of Hexokinase type III activity after 6 h, at 0 degrees celsius, at 10 mM |
CHEMBL1122206 |
| Unchecked |
Km |
= |
210000.0 |
nM |
Evaluated for the inhibition constant KM against hexokinase in yeast |
CHEMBL1122168 |
| Hexokinase type II |
Km |
= |
710000.0 |
nM |
Evaluated for the inhibition constant KM against Hexokinase, type II |
CHEMBL1122168 |
| Thymidine kinase |
Km |
= |
180000.0 |
nM |
Evaluated for the inhibition constant KM against rat cytoplasmic soluble thymidine kinase |
CHEMBL1122168 |
| Thymidine kinase |
Km |
= |
190000.0 |
nM |
Evaluated for the inhibition constant KM against rat mitochondrial thymidine kinase |
CHEMBL1122168 |
| P2Y purinoceptor 1 |
EC50 |
= |
2800.0 |
nM |
Activation of Purinoceptor P2Y1-mediated phospholipase C in turkey erythrocyte membranes |
CHEMBL1135410 |
| Purinergic receptor P2Y1 |
EC50 |
= |
1500.0 |
nM |
Accumulation of inositol phosphate in 1321N1 astrocytoma cells expressing human P2Y1 purinoceptor |
CHEMBL1135410 |
| Purinergic receptor P2Y2 |
EC50 |
= |
85.0 |
nM |
Agonist activity by measuring inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing human P2Y purinoceptor 2 |
CHEMBL1135410 |
| Pyrimidinergic receptor P2Y4 |
NE |
|
|
|
Agonist activity by measuring inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing human P2Y purinoceptor 4; No effect as either agonist or antagonist at 10 uM |
CHEMBL1135410 |
| Purinergic receptor P2Y11 |
EC50 |
= |
17300.0 |
nM |
Agonist activity by measuring inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing human P2Y purinoceptor 11 |
CHEMBL1135410 |
| Ectonucleoside triphosphate diphosphohydrolase 1 |
Activity |
= |
100.0 |
% |
Hydrolysis rate as substrate of rat Ectonucleoside triphosphate diphosphohydrolase 1 (NTPDase 1) (Ecto-apyrase) |
CHEMBL1135410 |
| Ectonucleoside triphosphate diphosphohydrolase 2 |
Activity |
= |
100.0 |
% |
Hydrolysis rate as substrate of rat Ectonucleoside triphosphate diphosphohydrolase 2 (NTPDase 2) (Ecto-apyrase) |
CHEMBL1135410 |
| Unchecked |
Kd |
= |
10000.0 |
nM |
Affinity for mouse cyclic-AMP dependent Ser/Thr Kinase |
CHEMBL1130008 |
| Unchecked |
Relative activity |
= |
100.0 |
% |
Compound was evaluated for nucleoside diphosphate kinase (NDP-kinase) activity |
CHEMBL1149985 |
| Adenylate kinase 2 |
Ki |
= |
90000.0 |
nM |
Inhibitory activity against rat adenylate kinase II was determined in the presence of ATP, non competitive inhibition |
CHEMBL1121949 |
| Adenylate kinase 1 |
Ki |
= |
570000.0 |
nM |
Inhibitory activity against rat Adenylate kinase M isoenzyme in the presence of ATP non competitive inhibition |
CHEMBL1121949 |
| S-adenosylmethionine synthetase alpha and beta forms |
Km |
= |
140000.0 |
nM |
Inhibitory constant against rat liver Methionine adenosyltransferase I, activity expressed as conc of Mg-ATP for half maximal velocity |
CHEMBL1123521 |
| S-adenosylmethionine synthetase alpha and beta forms |
Relative Vmax |
= |
100.0 |
|
Half maximal velocity relative to Methionine adenosyltransferase |
CHEMBL1123521 |
| S-adenosylmethionine synthetase gamma form |
Km |
= |
140000.0 |
nM |
Inhibitory constant against rat kidney Methionine adenosyltransferase II, activity expressed as conc of Mg-ATP for half maximal velocity |
CHEMBL1123521 |
| S-adenosylmethionine synthetase gamma form |
Relative Vmax |
= |
100.0 |
|
Half maximal velocity relative to rat Methionine adenosyltransferase II |
CHEMBL1123521 |
| S-adenosylmethionine synthetase (MAT 1 and MAT 2) |
Km |
= |
140000.0 |
nM |
Inhibition of methionine adenosyltransferase in Novikoff Hepatoma(MAT-T), activity expressed as conc of Mg-ATP for half maximal velocity |
CHEMBL1123521 |
| S-adenosylmethionine synthetase (MAT 1 and MAT 2) |
Relative Vmax |
= |
100.0 |
|
Half maximal velocity relative to methionine adenosyltransferase |
CHEMBL1123521 |
| No relevant target |
pKa |
= |
6.6 |
|
The pKa value was measured at 31-P chemical shift changes due to protonation |
CHEMBL1126903 |
| Dihydroorotase |
Activity |
= |
100.0 |
% |
Compound was evaluated for its effect on the activity of mammalian Carbamoyl-phosphate synthetase in the multienzyme polypeptide CAD at a concentration of 4mM |
CHEMBL1129083 |
| Serine/threonine protein phosphatase 2A, 56 kDa regulatory subunit, alpha isoform |
Log Kd |
= |
-7.16 |
|
Binding affinity against Purine Nucleoside Phosphatase |
CHEMBL1135481 |
| Unchecked |
Km |
= |
9800000.0 |
nM |
Kinetic parameter against EryA, erythritol kinase of brucella abortus expressed in Escherichia coli |
CHEMBL1136600 |
| Unchecked |
k cat |
= |
230.0 |
s-1 |
Kinetic parameter against EryA, erythritol kinase of brucella abortus expressed in Escherichia coli |
CHEMBL1136600 |
| Unchecked |
Km |
= |
4800000.0 |
nM |
Kinetic parameters against EryA, erythritol kinase from Propionibacterium pentosaceum |
CHEMBL1136600 |
| Glycerol kinase |
Ki |
= |
200000.0 |
nM |
Tested for its binding affinity against glycerol kinase (ATP competitive inhibition) |
CHEMBL1130575 |
| No relevant target |
pKa |
= |
7.1 |
|
pKa value was evaluated |
CHEMBL1130575 |
| Purinergic receptor P2Y1 |
EC50 |
= |
590.0 |
nM |
Concentration required for calcium mobilization at rat purinergic 2Y1 receptor expressed in HEK 293 cells |
CHEMBL1138685 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Km |
= |
133000.0 |
nM |
Steady-state kinetic constant for Hepatitis C Virus NS5BRdRp |
CHEMBL1143599 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Vmax |
= |
0.23 |
uM/min |
Incorporation efficiency for Hepatitis C Virus NS5BRdRp |
CHEMBL1143599 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Ratio |
= |
1700.0 |
|
Ratio of steady state kinetic constant and incorporation efficiency for Hepatitis C Virus NS5BRdRp |
CHEMBL1143599 |
| Heat shock protein 90 beta |
EC50 |
= |
19000.0 |
nM |
Inhibition of BODIPY-AG binding to dog Grp94 |
CHEMBL1137417 |
| Heat shock protein HSP90 |
EC50 |
= |
1500000.0 |
nM |
Inhibition of BODIPY-AG binding to human HSP90 |
CHEMBL1137417 |
| Ketopantoate reductase |
Activity |
|
|
|
Inhibition of Escherichia coli KPR at 1 mM |
CHEMBL1145346 |
| Ketopantoate reductase |
Kd |
= |
130000.0 |
nM |
Binding affinity to Escherichia coli KPR |
CHEMBL1145346 |
| Ketopantoate reductase |
Ki |
= |
610000.0 |
nM |
Inhibition of Escherichia coli KPR |
CHEMBL1145346 |
| Purinergic receptor P2Y2 |
EC50 |
= |
85.0 |
nM |
Agonist activity at human recombinant P2Y2 receptor expressed in 1321N1 cells assessed as stimulation of phospholipase C |
CHEMBL1142934 |
| Pyrimidinergic receptor P2Y4 |
Activity |
|
|
|
Antagonistic activity at human recombinant P2Y4 receptor expressed in 1321N1 cells |
CHEMBL1142934 |
| Pyrimidinergic receptor P2Y4 |
Kb |
= |
708.0 |
nM |
Antagonistic activity at human recombinant P2Y4 receptor expressed in 1321N1 cells |
CHEMBL1142934 |
| Pyrimidinergic receptor P2Y6 |
Activity |
|
|
|
Agonist activity at human recombinant P2Y6 receptor expressed in 1321N1 cells assessed as stimulation of phospholipase C at 10 uM |
CHEMBL1142934 |
| Unchecked |
Kcat/Km |
= |
0.00074 |
/uM/min |
Ratio of Kcat to Km for HCV NS5B RNA polymerase |
CHEMBL1142170 |
| Unchecked |
Kcat/Km |
= |
0.00064 |
/uM/min |
Ratio of Kcat to Km for HCV NS5B RNA polymerase S282T mutant |
CHEMBL1142170 |
| Unchecked |
Km |
= |
2700.0 |
nM |
Activity of HCV NS5B RNA polymerase assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
| Unchecked |
Kcat |
= |
0.002 |
/s |
Activity of HCV NS5B RNA polymerase assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Km |
= |
260.0 |
nM |
Activity of HCV NS5B RNA polymerase S282T assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
Kcat |
= |
0.000167 |
/s |
Activity of HCV NS5B RNA polymerase S282T assessed as incorporation of 32P-UMP into RNA |
CHEMBL1142170 |
| Serum |
T1/2 |
= |
2.0 |
hr |
Stability in fetal calf serum at 500 uM at 37 degC |
CHEMBL1149314 |
| CCRF-CEM |
T1/2 |
= |
0.25 |
hr |
Stability in CEM cell extract |
CHEMBL1149314 |
| Unchecked |
Km |
= |
530000.0 |
nM |
Activity of wild type MDD in rat liver |
CHEMBL1137532 |
| Diphosphomevalonate decarboxylase |
Km |
= |
1870000.0 |
nM |
Activity of MDD K27A mutant |
CHEMBL1137532 |
| Diphosphomevalonate decarboxylase |
Km |
= |
1400000.0 |
nM |
Activity of MDD R154A mutant |
CHEMBL1137532 |
| Unchecked |
Km |
= |
110000.0 |
nM |
Incorporation of Poliovirus RNA dependent RNA polymerase into sym/sub-C primer |
CHEMBL1140696 |
| Unchecked |
Kcat |
= |
0.82 |
10^-4/s |
Incorporation of Poliovirus RNA dependent RNA polymerase into sym/sub-C primer |
CHEMBL1140696 |
| Unchecked |
Kcat/Km |
= |
0.74 |
10^-6 microM/s |
Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-C primer relative to control |
CHEMBL1140696 |
| Serine/threonine-protein kinase Aurora-A |
Ka |
= |
5.7 |
/uM |
Binding affinity to human AURA expressed in baculovirus |
CHEMBL1143242 |
| Serine/threonine-protein kinase Aurora-A |
Ka |
= |
27.5 |
/nM |
Binding affinity to human AURA expressed in baculovirus in presence of anacardic acid |
CHEMBL1143242 |
| Purinergic receptor P2Y12 |
Inhibition |
= |
63.0 |
% |
Antagonist activity at P2Y12 receptor assessed as inhibition of ADP-induced human platelet aggregation by washed platelet assay at 100 uM |
CHEMBL1141591 |
| Pyrimidinergic receptor P2Y6 |
Activity |
|
|
|
Effect on P2Y6 receptor-mediated cell motility in Wistar rat microglia assessed as formation of lamellipodia-like membrane ruffles at 10 uM after 5 mins |
CHEMBL1147977 |
| Pyrimidinergic receptor P2Y6 |
Activity |
|
|
|
Effect on P2Y6 receptor-mediated cell motility in Wistar rat microglia at 100 uM by chemotaxis assay |
CHEMBL1147977 |
| Testis-specific serine/threonine-protein kinase 1 |
Km |
= |
50500.0 |
nM |
Activity at TSSK1 by Michaelis-Menten plot |
CHEMBL1137782 |
| Serum |
T1/2 |
= |
3.6 |
hr |
Metabolic stability in human serum assessed as hydrolysis half life at 0.25 mM measured for 18 hrs by HPLC |
CHEMBL1137702 |
| Serum |
T1/2 |
= |
7.7 |
hr |
Metabolic stability in human serum assessed as hydrolysis half life at 40 mM measured for 6 days by HPLC |
CHEMBL1137702 |
| Unchecked |
Km |
> |
400.0 |
nM |
Activity of Neisseria meningitidis 2C43 HldA in presence of 0.2 uM D-glycero-D-manno-heptose-7-phosphate |
CHEMBL1143345 |
| Unchecked |
Km |
> |
800.0 |
nM |
Activity of Escherichia coli O18:K1 C7 HldE in presence of 0.2 uM D-glycero-D-manno-heptose-7-phosphate |
CHEMBL1143345 |
| Unchecked |
Km |
= |
147000.0 |
nM |
Activity of Escherichia coli O18:K1 C7 HldE in presence of 1.8 uM D-glycero-D-manno-heptose-7-phosphate |
CHEMBL1143345 |
| Ribokinase |
Km |
= |
18000.0 |
nM |
Activity of Escherichia coli K12 MG1655 ribokinase in presence of 3 uM D-ribose |
CHEMBL1143345 |
| Purinergic receptor P2Y2 |
EC50 |
= |
95.8 |
nM |
Agonist activity at N-terminal HA epitope-tagged wild type 3 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
41.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
1000.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Ratio EC50 |
= |
4.0 |
|
Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor R177A_R180A double mutant to EC50 for wild type 4 human P2Y2 receptor |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
97.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Ratio EC50 |
= |
2.0 |
|
Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor Y114A mutant to EC50 for wild type 3 human P2Y2 receptor |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
63.1 |
nM |
Agonist activity at N-terminal HA epitope-tagged wild type 4 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
30.1 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y114A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
239.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A_R180A double mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
183.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
237.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R180A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
11700.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R272A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
299.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
111.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R194H mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
= |
120.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y198A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
EC50 |
> |
300000.0 |
nM |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor S296A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
110.0 |
% |
Agonist activity at N-terminal HA epitope-tagged wild type 4 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
87.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y114A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
104.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A_R180A double mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
117.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
115.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R180A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
87.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R272A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
92.0 |
% |
Agonist activity at N-terminal HA epitope-tagged wild type 3 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
130.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R194H mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
126.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y198A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Efficacy |
= |
5.0 |
% |
Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor S296A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Activity |
|
|
|
Agonist activity at N-terminal HA epitope-tagged wild type human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Ratio EC50 |
= |
3.0 |
|
Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant to EC50 for wild type 3 human P2Y2 receptor |
CHEMBL1138525 |
| Purinergic receptor P2Y2 |
Ratio EC50 |
= |
10.0 |
|
Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant to EC50 for wild type 3 human P2Y2 receptor |
CHEMBL1138525 |
| Unchecked |
IC50 |
= |
500.0 |
nM |
Displacement of fluorescein labeled N6-(6-amino)hexyl-ATP-5-FAM from HSP70 by fluorescence polarization assay |
CHEMBL1152808 |
| Unchecked |
Kd |
|
|
|
Binding affinity to HSP70 by Biocore direct binding assay |
CHEMBL1152808 |
| Unchecked |
IC50 |
> |
400000.0 |
nM |
Binding affinity to HSP90 by fluorescence polarization assay |
CHEMBL1152808 |
| Purinergic receptor P2Y2 |
EC50 |
= |
85.0 |
nM |
Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells coexpressing phospholipase C-activating G protein assessed as inositol phosphate production by scintillation proximity assay |
CHEMBL1136919 |
| MAP kinase-activated protein kinase 2 |
IC50 |
= |
2800.0 |
nM |
Inhibition of human recombinant phospho-MK2 (36-400) by HTRF assay |
CHEMBL1153133 |
| MAP kinase-activated protein kinase 2 |
IC50 |
= |
6300.0 |
nM |
Displacement of [8-3H]ATP from human recombinant MK2 (36-400) by scintillation proximity assay |
CHEMBL1153133 |
| MAP kinase-activated protein kinase 2 |
IC50 |
= |
12000.0 |
nM |
Displacement of [8-3H]ATP from human recombinant MK2 (41-364) by scintillation proximity assay |
CHEMBL1153133 |
| Purinergic receptor P2Y1 |
EC50 |
= |
200.0 |
nM |
Agonist activity at P2Y1 receptor expressed in human HEK293 cells |
CHEMBL1157627 |
| Serum |
T1/2 |
= |
4.9 |
hr |
Half life in human serum |
CHEMBL1156201 |
| Tyrosine-protein kinase ABL |
Activity |
|
|
|
Displacement of abl from GNF2 resin using affinity chromatography at 1000 uM by competition binding assay |
CHEMBL1240306 |
| Unchecked |
Activity |
|
|
|
Induction of P2Y mediated TRPC5 S-nitrosylation in in chicken DT40 cells assessed as increase in Ca2+ level from extracellular space at 100 uM in presence of PLC-beta inhibitor U73122 |
CHEMBL1250444 |
| Unchecked |
Kcat |
= |
43.3 |
/s |
Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Km |
= |
16300.0 |
nM |
Activity of Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Kcat |
= |
12.1 |
/s |
Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Km |
= |
5600.0 |
nM |
Activity of Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Kcat |
= |
21.4 |
/s |
Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Km |
= |
29500.0 |
nM |
Activity of Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Kcat/Km |
= |
2.7 |
10'6/M/s |
Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Kcat/Km |
= |
2.2 |
10'6/M/s |
Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a N196D/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Unchecked |
Kcat/Km |
= |
7.2 |
10'5/M/s |
Ratio of Kcat to Km for Aminoglycoside 2'-phosphotransferase 2a R92H/D268N mutant using ATP/GTP as second substrate by spectrophotometric assay |
CHEMBL1255425 |
| Epidermal growth factor receptor erbB1 |
Km |
= |
17000.0 |
nM |
Binding affinity to EGFR |
CHEMBL1268867 |
| Unchecked |
Km |
= |
70000.0 |
nM |
Binding affinity to FGFR |
CHEMBL1268867 |
| Serine/threonine-protein kinase AKT2 |
Km |
= |
254000.0 |
nM |
Binding affinity to Akt2 |
CHEMBL1268867 |
| Serine/threonine-protein kinase Aurora-B |
Km |
= |
34000.0 |
nM |
Binding affinity to aurora B |
CHEMBL1268867 |
| Cyclin-dependent kinase 2/cyclin E |
Km |
= |
3600.0 |
nM |
Binding affinity to CDK2/cyclin E |
CHEMBL1268867 |
| Serine/threonine-protein kinase Chk1 |
Km |
= |
1400.0 |
nM |
Binding affinity to CHK1 |
CHEMBL1268867 |
| Unchecked |
Kd |
= |
134000.0 |
nM |
Binding affinity to Poliovirus RNA-dependent RNA polymerase |
CHEMBL1269004 |
| Prelamin-A/C |
Potency |
= |
5.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Heat shock 70 kDa protein 1 |
IC50 |
= |
3370.0 |
nM |
PUBCHEM_BIOASSAY: In Vitro Hsp70 Dose Response Fluorescence Polarization Assay for SAR Study. (Class of assay: confirmatory) [Related pubchem assays: 786, 583 ] |
CHEMBL1201862 |
| Glyceraldehyde-3-phosphate dehydrogenase liver |
IC50 |
> |
100000.0 |
nM |
PUBCHEM_BIOASSAY: GAPDH Dose Response Colorimetric Assay. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Heat shock cognate 71 kDa protein |
IC50 |
= |
17300.0 |
nM |
PUBCHEM_BIOASSAY: In Vitro Hsc70 Dose Response Fluorescence Polarization Assay. (Class of assay: confirmatory) [Related pubchem assays: 1072 ] |
CHEMBL1201862 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents |
CHEMBL1697731 |
| 6-phospho-1-fructokinase |
Potency |
|
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485367, AID485368, AID488768] |
CHEMBL1201862 |
| Pantothenate synthetase |
Activity |
= |
42.6 |
% |
Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by circular dichroism spectra analysis (Rvb = 47.93 %%) |
CHEMBL1795340 |
| Pantothenate synthetase |
Activity |
= |
9.77 |
% |
Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by circular dichroism spectra analysis (Rvb = 8.19 %%) |
CHEMBL1795340 |
| Pantothenate synthetase |
Activity |
= |
2.0 |
10'10L/mol/s |
Binding affinity to Mycobacterium tuberculosis pantothenate synthetase by tryptophan fluorescence quenching assay |
CHEMBL1795340 |
| Purinergic receptor P2Y1 |
EC50 |
= |
150.0 |
nM |
Agonist activity at GFP tagged-human P2Y1 receptor expressed in human 1321N1 cells assessed as elevation in calcium level after 30 mins by fluorescence spectrophotometric analysis |
CHEMBL1799960 |
| Purinergic receptor P2Y11 |
EC50 |
= |
3300.0 |
nM |
Agonist activity at GFP tagged-human P2Y11 receptor expressed in human 1321N1 cells assessed as elevation in calcium level after 30 mins by fluorescence spectrophotometric analysis |
CHEMBL1799960 |
| Plasmodium falciparum |
Potency |
|
19011.5 |
nM |
PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] |
CHEMBL1201862 |
| Luciferin 4-monooxygenase |
Potency |
|
11423.9 |
nM |
PUBCHEM_BIOASSAY: Biochemical firefly luciferase enzyme assay for NPC. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Glucagon-like peptide 1 receptor |
Potency |
|
25118.9 |
nM |
PubChem BioAssay. qHTS of GLP-1 Receptor Agonists. (Class of assay: confirmatory) |
CHEMBL1201862 |
| P2X purinoceptor 4 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity at mouse P2X4 receptor by cell-based calcium influx assay |
CHEMBL2177033 |
| P2X purinoceptor 4 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity at rat P2X4 receptor by cell-based calcium influx assay |
CHEMBL2177033 |
| P2X purinoceptor 4 |
EC50 |
= |
1000.0 |
nM |
Antagonist activity at human P2X4 receptor expressed in 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx compound preincubated for 30 mins before ATP treatment by Fluo-4 AM fluorescence method |
CHEMBL2177033 |
| Purinergic receptor P2Y1 |
EC50 |
= |
200.0 |
nM |
Agonist activity at rat P2Y1R expressed in HEK293 cells assessed as release of intracellular calcium by fluorescence based assay |
CHEMBL2177082 |
| Streptavidin |
Activity |
|
|
|
Binding affinity to Streptomyces avidinii assessed as changes in protein fluorescence intensity by fluorescence spectral analysis method |
CHEMBL2202973 |
| Streptavidin |
Activity |
|
|
|
Binding affinity to Streptomyces avidinii streptavidin at 4 mM using dye labeled Streptavidin binding aptamer by fluorescence spectral analysis method |
CHEMBL2202973 |
| MDCK |
Activity |
|
|
|
Induction of intracellular calcium level in MDCK cells at 10 uM by Fura-2 in calcium free medium in presence of 10 uM U73343 inactive analogue of U73122 phospholipase C inhibitor |
CHEMBL2203169 |
| MDCK |
Activity |
= |
132.0 |
nM |
Induction of intracellular calcium level in MDCK cells assessed as net peak value at 10 uM by Fura-2 in calcium free medium |
CHEMBL2203169 |
| MDCK |
Activity |
|
|
|
Induction of intracellular calcium level in MDCK cells at 10 uM by Fura-2 in calcium free medium in presence of phospholipase C inhibitor U73122 |
CHEMBL2203169 |
| PC-12 |
Inhibition |
= |
45.0 |
% |
Antioxidant activity in rat PC12 cells assessed as inhibition of Fe2+-induced ROS production at 100 uM after 1 hr by DCFH-DA staining-based fluorometric analysis relative to control |
CHEMBL2384903 |
| PC-12 |
IC50 |
|
|
|
Antioxidant activity in rat PC12 cells assessed as inhibition of Fe2+-induced ROS production after 1 hr by DCFH-DA staining-based fluorometric analysis |
CHEMBL2384903 |
| NON-PROTEIN TARGET |
IC50 |
= |
60000.0 |
nM |
Antioxidant activity assessed as free radical scavenging activity after 7 mins by ABTS radical cation decolorization assay |
CHEMBL2384903 |
| NON-PROTEIN TARGET |
IC50 |
> |
500000.0 |
nM |
Antioxidant activity assessed as inhibiton of Fe2+-induced Fenton reaction-mediated hydroxyl radical formation from H2O2 measured for 150 secs by ESR analysis in presence of DMPO |
CHEMBL2384903 |
| Purinergic receptor P2Y11 |
EC50 |
= |
6700.0 |
nM |
Agonist activity at human GFP-tagged P2Y11R transfected in human 1321N1 cells assessed as induction of intracellular calcium mobilization by fluorescence assay |
CHEMBL2384903 |
| Purinergic receptor P2Y1 |
EC50 |
= |
850.0 |
nM |
Agonist activity at human GFP-tagged P2Y1R transfected in human 1321N1 cells assessed as induction of intracellular calcium mobilization by fluorescence assay |
CHEMBL2384903 |
| Unchecked |
Ki |
= |
18.0 |
nM |
Displacement of [35S]ATP-alphaS from purinergic P2Y receptor Wistar rat brain after 60 mins |
CHEMBL2390918 |
| Unchecked |
IC50 |
= |
18.0 |
nM |
Displacement of [35S]ATP-alphaS from purinergic P2Y receptor Wistar rat brain after 60 mins |
CHEMBL2390918 |
| Unchecked |
Inhibition |
= |
22.0 |
% |
Displacement of [35S]ATP-alphaS from purinergic P2Y receptor Wistar rat brain at 10 uM after 60 mins relative to control |
CHEMBL2390918 |
| Heat shock protein 75 kDa, mitochondrial |
Activity |
= |
31.3 |
uM |
Binding affinity to TRAP1 (unknown origin) |
CHEMBL2417440 |
| Unchecked |
Ratio |
= |
10.0 |
|
Ratio of binding affinity to HASP90 (unknown origin) to TRAP1 (unknown origin) |
CHEMBL2417440 |
| Endoplasmin |
Activity |
= |
3.4 |
uM |
Binding affinity to GRP94 (unknown origin) |
CHEMBL2417440 |
| Heat shock protein HSP90 |
Activity |
= |
840.0 |
uM |
Binding affinity to HSP90 (unknown origin) |
CHEMBL2417440 |
| Heat shock protein 75 kDa, mitochondrial |
IC50 |
= |
31303.0 |
nM |
Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant human Trap-1 after 24 hrs by fluorescence polarization assay |
CHEMBL2417440 |
| Heat shock protein 90 beta |
IC50 |
= |
3241.0 |
nM |
Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from dog Grp94 after 24 hrs by fluorescence polarization assay |
CHEMBL2417440 |
| Heat shock protein HSP 90-beta |
IC50 |
= |
893677.0 |
nM |
Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from recombinant HSP90beta (unknown origin) after 24 hrs by fluorescence polarization assay |
CHEMBL2417440 |
| Heat shock protein HSP 90-alpha |
IC50 |
= |
861330.0 |
nM |
Displacement of 5-(3-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid from HSP90alpha (unknown origin) after 24 hrs by fluorescence polarization assay |
CHEMBL2417440 |
| Tyrosine-protein kinase receptor UFO |
Km |
= |
100000.0 |
nM |
Inhibition of human AXL (unknown origin) using EAIYAAPFAKKK peptide as substrate by nanoliter kinase assay |
CHEMBL3091431 |
| ALK tyrosine kinase receptor |
Km |
= |
50000.0 |
nM |
Inhibition of human ALK (unknown origin) using poly[Glu:Tyr] as substrate by nanoliter kinase assay |
CHEMBL3091431 |
| Hepatocyte growth factor receptor |
Km |
= |
10000.0 |
nM |
Inhibition of human c-Met using KKKSPGEYVNIEFG peptide as substrate by nanoliter kinase assay |
CHEMBL3091431 |
| No relevant target |
pKa |
= |
7.1 |
|
Conversion of compound to its pyrophosphate assessed as acid dissociation constant (second deprotonation) |
CHEMBL3217618 |
| Thymidine kinase, cytosolic |
Activity |
= |
100.0 |
% |
Effect on thymidine kinase in BHK21 (C13) cells using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+ |
CHEMBL3227986 |
| Thymidine kinase, cytosolic |
Activity |
= |
100.0 |
% |
Effect on human cytoplasmic thymidine kinase using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+ |
CHEMBL3227986 |
| Thymidine kinase, mitochondrial |
Activity |
= |
100.0 |
% |
Effect on human mitochondrial thymidine kinase using [14C]thymidine at 5 mM after 10 mins by liquid scintillation spectrometer analysis relative to control in presence of Mg2+ |
CHEMBL3227986 |
| Adenylate kinase 2 |
Km |
= |
90000.0 |
nM |
Activity of Sprague-Dawley rat liver adenylate kinase 2 by Lineweaver-Burk plot analysis |
CHEMBL3244193 |
| Adenylate kinase 2 |
Vmax |
= |
100.0 |
% |
Activity of Sprague-Dawley rat liver adenylate kinase 2 by Lineweaver-Burk plot analysis relative to ATP |
CHEMBL3244193 |
| Adenylate kinase 3 alpha like 1 |
Km |
= |
90000.0 |
nM |
Activity of Sprague-Dawley rat liver adenylate kinase 3 by Lineweaver-Burk plot analysis |
CHEMBL3244193 |
| Adenylate kinase 3 alpha like 1 |
Vmax |
= |
100.0 |
% |
Activity of Sprague-Dawley rat liver adenylate kinase 3 by Lineweaver-Burk plot analysis relative to ATP |
CHEMBL3244193 |
| Adenylate kinase 1 |
Km |
= |
650000.0 |
nM |
Activity of Sprague-Dawley rat muscle adenylate kinase by Lineweaver-Burk plot analysis |
CHEMBL3244193 |
| Adenylate kinase 1 |
Vmax |
= |
100.0 |
% |
Activity of Sprague-Dawley rat muscle adenylate kinase by Lineweaver-Burk plot analysis relative to ATP |
CHEMBL3244193 |
| Unchecked |
Vmax |
= |
0.06 |
% |
Activity of Escherichia coli adenylate kinase by Lineweaver-Burk plot analysis relative to ATP |
CHEMBL3244193 |
| Uracil nucleotide/cysteinyl leukotriene receptor |
Activity |
|
|
|
Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes up to 1 mM after 60 mins by liquid scintillation counting |
CHEMBL3259593 |
| Ectonucleoside triphosphate diphosphohydrolase 1 |
Drug metabolism |
= |
807.0 |
nmol/min/mg |
Drug metabolism assessed as human NTPDase-1-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Ectonucleoside triphosphate diphosphohydrolase 2 |
Drug metabolism |
= |
1051.0 |
nmol/min/mg |
Drug metabolism assessed as human NTPDase-2-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Ectonucleoside triphosphate diphosphohydrolase 3 |
Drug metabolism |
= |
240.0 |
nmol/min/mg |
Drug metabolism assessed as human NTPDase-3-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Ectonucleoside triphosphate diphosphohydrolase 8 |
Drug metabolism |
= |
122.0 |
nmol/min/mg |
Drug metabolism assessed as human NTPDase-8-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 |
Drug metabolism |
= |
67.0 |
nmol/min/mg |
Drug metabolism assessed as human NPP1-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 |
Drug metabolism |
= |
54.0 |
nmol/min/mg |
Drug metabolism assessed as human NPP3-mediated compound hydrolysis expressed in African green monkey COS7 cells at 100 uM after 1 hr by HPLC analysis |
CHEMBL3286381 |
| Purinergic receptor P2Y1 |
EC50 |
= |
850.0 |
nM |
Agonist activity at human P2Y1 receptor expressed in human 1321N1 cells assessed as increase of intracellular calcium level after 30 mins using fura-2 AM by fluorescence assay |
CHEMBL3286381 |
| Adenosine kinase |
Activity |
= |
100.0 |
% |
Binding affinity to human ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-1' at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Adenosine kinase |
Activity |
< |
1.0 |
% |
Binding affinity to human ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-2 at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Adenosine kinase |
Activity |
< |
1.0 |
% |
Binding affinity to human ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-8 at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Unchecked |
Activity |
= |
100.0 |
% |
Binding affinity to Mycobacterium tuberculosis ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-1' at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Unchecked |
Activity |
= |
57.0 |
% |
Binding affinity to Mycobacterium tuberculosis ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-2 at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Unchecked |
Activity |
= |
24.0 |
% |
Binding affinity to Mycobacterium tuberculosis ADK expressed in Escherichia coli BL21(DE3) cells assessed as relative STD enhancements of signal from H-8 at 500 uM by 1H STD NMR spectroscopy |
CHEMBL3352218 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.64 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SPQKPIVR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.78 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as VFLPNK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.97 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as 7VVPAR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.76 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DSLKK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.75 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SIPIPQPFRPADEDHR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.68 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as GDGGSTTGLSATPPASLPGSLTNVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.62 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DSSDDWEIPDGQITVGQR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.62 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as IGSGSFGTVYK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.75 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as WHGDVAVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.34 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as NEVGVLR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.54 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as LIDIAR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.81 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as QTAQGMDYLHAK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
1.16 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SIIHRDLK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.77 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SNNIFLHEDLTVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.72 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as IGDFGLATVK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.57 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as DQIIFMVGR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.76 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as GYLSPDLSK accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.94 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as SASEPSLNR accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Serine/threonine-protein kinase B-raf |
Ratio |
= |
0.95 |
|
Binding affinity to recombinant human full-length wild type B-Raf (unknown origin) assessed as TPIQAGGYGAFPVH accessible protease cleavage peptide level by LC-MS/MS analysis relative to control |
CHEMBL3414549 |
| Purinergic receptor P2Y11 |
EC50 |
= |
6700.0 |
nM |
Agonist activity at GFP-tagged human P2Y11R transfected in human 1321N1 cells assessed as increase in intracellular Ca2+ level by fura 2/AM probe-based fluorescence assay |
CHEMBL3632592 |
| Purinergic receptor P2Y1 |
EC50 |
= |
850.0 |
nM |
Agonist activity at GFP-tagged human P2Y1R transfected in human 1321N1 cells assessed as increase in intracellular Ca2+ level by fura 2/AM probe-based fluorescence assay |
CHEMBL3632592 |
| No relevant target |
IC50 |
= |
60000.0 |
nM |
Antioxidant activity assessed as ABTS radical scavenging activity after 7 mins |
CHEMBL3632592 |
| PC-12 |
IC50 |
|
|
|
Antioxidant activity in rat PC12 cells assessed as inhibition of Fe2+-induced reactive oxygen species formation after 1 hr by DCFH-DA dye-based fluorometric analysis |
CHEMBL3632592 |
| Unchecked |
Activity |
|
|
|
Activity of Bacillus subtilis N-terminal His-tagged ANT(6) expressed in Escherichia coli BL21(DE3) cells assessed as adenylated product by Michaelis-Menten kinetics |
CHEMBL3779814 |
| Purinergic receptor P2Y12 |
IC50 |
= |
251188.64 |
nM |
Antagonist activity at P2Y12 receptor in human platelets assessed as inhibition of ADP-induced platelet aggregation by turbidimetric method |
CHEMBL3797132 |
| CDGSH iron-sulfur domain-containing protein 1 |
IC50 |
|
|
|
Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay |
CHEMBL3862005 |
| CDGSH iron-sulfur domain-containing protein 1 |
Ki |
|
|
|
Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis |
CHEMBL3862005 |
| Mitogen-activated protein kinase kinase kinase 7 |
Kd |
= |
2800.0 |
nM |
Binding affinity to recombinant human biotinylated N-terminal GST-tagged autophosphorylated TAK1 (1 to 303 residues) fused with TAB1 (437 to 504 residues) expressed in baculovirus infected sf9 cells by SPR assay |
CHEMBL4002626 |
| Unchecked |
IC50 |
= |
27000.0 |
nM |
Inhibition of BODIPY-FL-ATPgammaS binding to Thermotoga maritima His-tagged HK853 expressed in Escherichia coli BL21(DE3)pLysS Rosetta after 25 mins by fluorescence polarization assay |
CHEMBL4017529 |
| Unchecked |
Ratio EC50 |
= |
350.0 |
|
Selectivity ratio of EC50 for P2Y2 receptor R272A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin) |
CHEMBL4017533 |
| NACHT, LRR and PYD domains-containing protein 3 |
Activity |
|
|
|
Agonist activity at NLRP3 in human THLP1-null cells assessed as induction of LPS-induced IL-1beta secretion by HEK-Blue reporter cell based assay |
CHEMBL4024746 |
| HSP90 |
Activity |
|
|
|
Binding affinity to Plasmodium falciparum HSP90 nucleotide binding domain at 0.5 mM by SYPRO orange dye based DSF analysis |
CHEMBL4152256 |
| Unchecked |
Activity |
|
|
|
Binding affinity to Plasmodium falciparum GRP94 nucleotide binding domain at 0.5 mM by SYPRO orange dye based DSF analysis |
CHEMBL4152256 |
| Unchecked |
Kd |
= |
37.0 |
nM |
Displacement of Cy5-labelled (position-4) ATP from human HSP70 expressed in Escherichia coli BL21(DE3) after 16 hrs by microarray assay |
CHEMBL4177614 |
| Unchecked |
Kd |
= |
37.0 |
nM |
Displacement of Cy5-labelled (position-4) ATP from Mycobacterium tuberculosis HSP70 expressed in Escherichia coli BL21(DE3) after 16 hrs by microarray assay |
CHEMBL4177614 |
| Unchecked |
EC50 |
= |
1.0 |
nM |
Displacement of Cy5-labelled (position-4) ATP from human HSP70 expressed in Escherichia coli BL21(DE3) after 16 hrs by microarray assay |
CHEMBL4177614 |
| Unchecked |
EC50 |
= |
1.0 |
nM |
Displacement of Cy5-labelled (position-4) ATP from Mycobacterium tuberculosis HSP70 expressed in Escherichia coli BL21(DE3) after 16 hrs by microarray assay |
CHEMBL4177614 |
| Purinergic receptor P2Y2 |
EC50 |
= |
230.0 |
nM |
Agonist activity at P2Y2 receptor (unknown origin) |
CHEMBL4184187 |
| Purinergic receptor P2Y2 |
EC50 |
= |
180.0 |
nM |
Agonist activity at P2Y2 receptor in NG108-15 cells (unknown origin) |
CHEMBL4184187 |
| Purinergic receptor P2Y2 |
EC50 |
= |
200.0 |
nM |
Agonist activity at P2Y2 receptor in human CF/T43 cells |
CHEMBL4184187 |
| Purinergic receptor P2Y2 |
EC50 |
= |
200.0 |
nM |
Agonist activity at P2Y2 receptor in BEA cells (unknown origin) |
CHEMBL4184187 |
| Cyclic GMP-AMP synthase |
Drug metabolism |
= |
0.0 |
% |
Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis |
CHEMBL4334523 |
| Cyclic GMP-AMP synthase |
Drug metabolism |
= |
57.0 |
% |
Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis |
CHEMBL4334523 |
| Unchecked |
Drug metabolism |
= |
0.0 |
% |
Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of GTP by HPLC-UV analysis |
CHEMBL4334523 |
| Cyclic GMP-AMP synthase |
Drug metabolism |
|
|
|
Substrate activity at recombinant full-length human CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis |
CHEMBL4334523 |
| Cyclic GMP-AMP synthase |
Drug metabolism |
|
|
|
Substrate activity at recombinant full-length mouse CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis |
CHEMBL4334523 |
| Unchecked |
Drug metabolism |
|
|
|
Substrate activity at recombinant full-length chicken CGAS expressed in Escherichia coli BL21 (DE3) assessed as cyclic dinucleotide formation by measuring reaction conversion at 1 mM incubated for 16 hrs in presence of ATP by HPLC-UV analysis |
CHEMBL4334523 |
| Tyrosine-protein kinase JAK2 |
Kd |
= |
1300.0 |
nM |
Binding affinity to wild type 6XHis-tagged human JAK2 JH2 domain (513 to 827 residues) expressed in baculovirus infected Sf9 cells by MANT-ATP binding assay |
CHEMBL4354882 |
| Tyrosine-protein kinase JAK2 |
Kd |
= |
1300.0 |
nM |
Binding affinity to 6XHis-tagged human JAK2 JH2 domain V617F mutant (513 to 827 residues) expressed in baculovirus infected Sf9 cells by MANT-ATP binding assay |
CHEMBL4354882 |
| Lipoxin A4 receptor |
Activity |
|
|
|
Agonist activity at ALX/FPR2 (unknown origin) expressed in HEK293 cells co-expressing Galphaq assessed as induction of intracellular calcium accumulation at 1 uM by Fluo-4 dye based fluorescence spectrophotometric assay |
CHEMBL4382216 |
| HEK293 |
Activity |
|
|
|
Induction of intracellular calcium accumulation in HEK293 cells at 1 uM by Fluo-4 dye based fluorescence spectrophotometric assay |
CHEMBL4382216 |
| Replicase polyprotein 1ab |
Inhibition |
= |
18.34 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.02 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.02 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| Unchecked |
Kd |
= |
2600.0 |
nM |
Binding affinity to Escherichia coli BL21 (DE3) HPPK incubated for 10 mins by fluorimetry |
CHEMBL4673295 |
| 78 kDa glucose-regulated protein |
Delta Tm |
= |
4.65 |
degrees C |
Binding affinity to N-terminal His-tagged GRP78 (unknown origin) assessed as change in melting temperature at 500 uM by differential scanning fluorimetry |
CHEMBL4680232 |
| RNA cytidine acetyltransferase |
Activity |
|
|
|
Stabilization of full length recombinant NAT10 (unknown origin) by DSLS based analysis |
CHEMBL4732272 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of recombinant human RAD51/p53 (unknown origin) interaction at 200 uM measured by ELISA assay |
CHEMBL5113497 |
